Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 29;397(10289):2043-2046.
doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw  1 , Arabella Stuart  1 , Melanie Greenland  1 , Xinxue Liu  1 , Jonathan S Nguyen Van-Tam  2 , Matthew D Snape  3 ; Com-COV Study Group
Affiliations

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2021 May 29;397(10289):2048. doi: 10.1016/S0140-6736(21)01156-9. Epub 2021 May 18. Lancet. 2021. PMID: 34019820 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Severity of solicited local and systemic reactions in days 0-7 after vaccination with ChAdOx1 nCoV-19 (ChAd) or BNT162b2 (BNT), by prime and boost vaccination and by vaccination group, as self-reported in participant electronic diaries ChAd/ChAd denotes a ChAd vaccine for prime and boost doses. ChAd/BNT denotes a ChAd vaccine for prime dose and a BNT vaccine for boost dose. BNT/BNT denotes a BNT vaccine for prime and boost doses. BNT/ChAd denotes a BNT for prime dose and a ChAd vaccine for boost dose. The severity presented is the participant's highest severity across 7 days after vaccination for each solicited adverse event. Fever was categorised as mild (38·0°C to <38·5°C), moderate (38·5°C to <39°C), or severe (≥39·0°C). Feverish was a self-reported feeling of feverishness. For systemic symptoms, grading was classified as mild (easily tolerated with no limitation on normal activity), moderate (some limitation of daily activity), and severe (unable to perform normal daily activity).
None
None
See this image and copyright information in PMC

Comment in

References

    1. Folkhälsomyndigheten - Public Health Agency of Sweden Information on the continued use of the Astra Zeneca vaccine in the vaccination of people 65 and older. March 26, 2021. http://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/co...
    1. Haute Authorité de Santé - French National Health Authority Covid-19: quelle stratégie vaccinale pour les moins de 55 ans ayant déj reçu une dose d'AstraZeneca? April 9, 2021. https://www.has-sante.fr/jcms/p_3260335/en/covid-19-quelle-strategie-vac...
    1. Sundhedsstyrelsen - Danish Health Authority Denmark continues its vaccine rollout without the COVID-19 vaccine from AstraZeneca. April 14, 2021. https://www.sst.dk/en/english/corona-eng/vaccination-against-covid-19/as...
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl Med. 2020;383:2603–2615. - PMC - PubMed
    1. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. - PMC - PubMed

Publication types

MeSH terms